BACKGROUND: Most studies of heart failure (HF) in Medicare beneficiaries have excluded patients age <65 years. We examined baseline characteristics, quality of care, and outcomes among younger and older Medicare beneficiaries hospitalized with HF in the Alabama Heart Failure Project. METHODS: Of the 8049 Medicare beneficiaries discharged alive with a primary discharge diagnosis of HF in 1998-2001 from 106 Alabama hospitals, 991 (12%) were younger (age <65 years). After excluding 171 patients discharge to hospice care, 7867 patients were considered eligible for left ventricular systolic function (LVSF) evaluation and 2211 patients with left ventricular ejection fraction <45% and without contraindications were eligible for angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy. RESULTS: Nearly half of the younger HF patients (45% versus 22% for ≥65 years; p<0.001) were African American. LVSF was evaluated in 72%, 72%, 70% and 60% (overall p<0.001) and discharge prescriptions of ACE inhibitors or ARBs were given to 83%, 77%, 75% and 75% of eligible patients (overall p=0.013) among those <65, 65-74, 75-84 and ≥85 years respectively. During 9 years of follow-up, all-cause mortality occurred in 54%, 61%, 71% and 80% (overall p<0.001) and hospital readmission due to worsening HF occurred in 65%, 60%, 55% and 48% (overall p<0.001) of those <65, 65-74, 75-84 and ≥85 years respectively. CONCLUSION: Medicare beneficiaries <65 years with HF, nearly half of whom were African American generally received better quality of care, had lower mortality, but had higher re-hospitalizations due to HF. Published by Elsevier Ireland Ltd.
BACKGROUND: Most studies of heart failure (HF) in Medicare beneficiaries have excluded patients age <65 years. We examined baseline characteristics, quality of care, and outcomes among younger and older Medicare beneficiaries hospitalized with HF in the Alabama Heart Failure Project. METHODS: Of the 8049 Medicare beneficiaries discharged alive with a primary discharge diagnosis of HF in 1998-2001 from 106 Alabama hospitals, 991 (12%) were younger (age <65 years). After excluding 171 patients discharge to hospice care, 7867 patients were considered eligible for left ventricular systolic function (LVSF) evaluation and 2211 patients with left ventricular ejection fraction <45% and without contraindications were eligible for angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy. RESULTS: Nearly half of the younger HF patients (45% versus 22% for ≥65 years; p<0.001) were African American. LVSF was evaluated in 72%, 72%, 70% and 60% (overall p<0.001) and discharge prescriptions of ACE inhibitors or ARBs were given to 83%, 77%, 75% and 75% of eligible patients (overall p=0.013) among those <65, 65-74, 75-84 and ≥85 years respectively. During 9 years of follow-up, all-cause mortality occurred in 54%, 61%, 71% and 80% (overall p<0.001) and hospital readmission due to worsening HF occurred in 65%, 60%, 55% and 48% (overall p<0.001) of those <65, 65-74, 75-84 and ≥85 years respectively. CONCLUSION: Medicare beneficiaries <65 years with HF, nearly half of whom were African American generally received better quality of care, had lower mortality, but had higher re-hospitalizations due to HF. Published by Elsevier Ireland Ltd.
Authors: Edward P Havranek; Frederick A Masoudi; Kelly A Westfall; Pam Wolfe; Diana L Ordin; Harlan M Krumholz Journal: Am Heart J Date: 2002-03 Impact factor: 4.749
Authors: Maciej Banach; Vikas Bhatia; Margaret A Feller; Marjan Mujib; Ravi V Desai; Mustafa I Ahmed; Jason L Guichard; Inmaculada Aban; Thomas E Love; Wilbert S Aronow; Michel White; Prakash Deedwania; Gregg Fonarow; Ali Ahmed Journal: Am J Cardiol Date: 2011-02-04 Impact factor: 2.778
Authors: Saif S Rathore; JoAnne M Foody; Yongfei Wang; Grace L Smith; Jeph Herrin; Frederick A Masoudi; Pamela Wolfe; Edward P Havranek; Diana L Ordin; Harlan M Krumholz Journal: JAMA Date: 2003-05-21 Impact factor: 56.272
Authors: Ali Ahmed; Richard M Allman; Catarina I Kiefe; Sharina D Person; Terrence M Shaneyfelt; Richard V Sims; George Howard; James F DeLong Journal: Am Heart J Date: 2003-06 Impact factor: 4.749
Authors: Helen M Sheriff; Manik R Thogaripally; Gurusher Panjrath; Cherinne Arundel; Qing Zeng; Gregg C Fonarow; Javed Butler; Ross D Fletcher; Charity Morgan; Marc R Blackman; Prakash Deedwania; Thomas E Love; Wilbert S Aronow; Stefan D Anker; Richard M Allman; Ali Ahmed Journal: J Am Med Dir Assoc Date: 2017-05-11 Impact factor: 4.669
Authors: Cherinne Arundel; Phillip H Lam; Rahul Khosla; Marc R Blackman; Gregg C Fonarow; Charity Morgan; Qing Zeng; Ross D Fletcher; Javed Butler; Wen-Chih Wu; Prakash Deedwania; Thomas E Love; Michel White; Wilbert S Aronow; Stefan D Anker; Richard M Allman; Ali Ahmed Journal: Am J Med Date: 2016-07-09 Impact factor: 4.965
Authors: Chakradhari Inampudi; Sridivya Parvataneni; Charity J Morgan; Prakash Deedwania; Gregg C Fonarow; Paul W Sanders; Sumanth D Prabhu; Javed Butler; Daniel E Forman; Wilbert S Aronow; Richard M Allman; Ali Ahmed Journal: Am J Cardiol Date: 2014-04-18 Impact factor: 2.778
Authors: Wilbert S Aronow; Michael W Rich; Sarah J Goodlin; Thomas Birkner; Yan Zhang; Margaret A Feller; Inmaculada B Aban; Linda G Jones; Donna M Bearden; Richard M Allman; Ali Ahmed Journal: J Am Med Dir Assoc Date: 2011-10-08 Impact factor: 4.669
Authors: Yan Zhang; Meredith L Kilgore; Tarun Arora; Marjan Mujib; O James Ekundayo; Inmaculada B Aban; Margaret A Feller; Ravi V Desai; Thomas E Love; Richard M Allman; Gregg C Fonarow; Ali Ahmed Journal: Int J Cardiol Date: 2011-11-25 Impact factor: 4.164
Authors: Ali Ahmed; Robert C Bourge; Gregg C Fonarow; Kanan Patel; Charity J Morgan; Jerome L Fleg; Inmaculada B Aban; Thomas E Love; Clyde W Yancy; Prakash Deedwania; Dirk J van Veldhuisen; Gerasimos S Filippatos; Stefan D Anker; Richard M Allman Journal: Am J Med Date: 2013-11-18 Impact factor: 4.965
Authors: Phillip H Lam; Poonam Bhyan; Cherinne Arundel; Daniel J Dooley; Helen M Sheriff; Selma F Mohammed; Gregg C Fonarow; Charity J Morgan; Wilbert S Aronow; Richard M Allman; Finn Waagstein; Ali Ahmed Journal: Clin Cardiol Date: 2018-03-22 Impact factor: 2.882
Authors: Ali Ahmed; Michael W Rich; Michael Zile; Paul W Sanders; Kanan Patel; Yan Zhang; Inmaculada B Aban; Thomas E Love; Gregg C Fonarow; Wilbert S Aronow; Richard M Allman Journal: Am J Med Date: 2013-02 Impact factor: 4.965
Authors: Kanan Patel; Gregg C Fonarow; Dalane W Kitzman; Inmaculada B Aban; Thomas E Love; Richard M Allman; Mihai Gheorghiade; Ali Ahmed Journal: JACC Heart Fail Date: 2013-02 Impact factor: 12.035
Authors: Kumar Sanam; Vikas Bhatia; Navkaranbir S Bajaj; Saurabh Gaba; Charity J Morgan; Gregg C Fonarow; Javed Butler; Prakash Deedwania; Sumanth D Prabhu; Wen-Chih Wu; Michel White; Thomas E Love; Wilbert S Aronow; Ross D Fletcher; Richard M Allman; Ali Ahmed Journal: Am J Med Date: 2016-06-02 Impact factor: 4.965